Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease

EF Balcom, A Nath, C Power - Brain, 2021 - academic.oup.com
Abstract Coronavirus disease 2019 (COVID-19) is a global pandemic caused by SARS-CoV-
2 infection and is associated with both acute and chronic disorders affecting the nervous …

Characteristics of viral pneumonia in the COVID-19 era: an update

P Pagliano, C Sellitto, V Conti, T Ascione, S Esposito - Infection, 2021 - Springer
Influenza virus, rhinovirus, and adenovirus frequently cause viral pneumonia, an important
cause of morbidity and mortality especially in the extreme ages of life. During the last two …

Practical recommendations for optimal thromboprophylaxis in patients with COVID-19: a consensus statement based on available clinical trials

KG Kyriakoulis, E Dimakakos, IG Kyriakoulis… - Journal of clinical …, 2022 - mdpi.com
Coronavirus disease 2019 (COVID-19) has been shown to be strongly associated with
increased risk for venous thromboembolism events (VTE) mainly in the inpatient but also in …

Flavonoids as a therapeutical option for the treatment of thrombotic complications associated with COVID‐19

JP Quintal Martinez… - Phytotherapy …, 2023 - Wiley Online Library
The SARS‐CoV‐2 outbreak has been one of the largest public health crises globally, while
thrombotic complications have emerged as an important factor contributing to mortality …

The effect of anakinra in hospitalized patients with COVID-19: an updated systematic review and meta-analysis

KG Kyriakoulis, A Kollias, G Poulakou… - Journal of clinical …, 2021 - mdpi.com
The role of immunomodulatory agents in the treatment of hospitalized patients with COVID-
19 has been of increasing interest. Anakinra, an interleukin-1 inhibitor, has been shown to …

High versus standard intensity of thromboprophylaxis in hospitalized patients with COVID-19: a systematic review and meta-analysis

A Kollias, KG Kyriakoulis, IP Trontzas, V Rapti… - Journal of clinical …, 2021 - mdpi.com
Thromboprophylaxis in hospitalized patients with COVID-19 has been associated with a
survival benefit and is strongly recommended. However, the optimal dose of …

[HTML][HTML] Thromboprophylaxis in COVID-19: Early initiation might be as important as optimal dosing

A Kollias, G Poulakou, E Dimakakos… - Thrombosis …, 2021 - ncbi.nlm.nih.gov
Moll et al. recently published a retrospective analysis of COVID-19 patients admitted to
intensive care unit (ICU) from a single tertiarycare academic hospital showing that there was …

Epidemiology, pathogenesis, and management of Coronavirus disease 2019-associated stroke

L Liu, C Zhou, H Jiang, H Wei, Y Zhou, C Zhou, X Ji - Frontiers of Medicine, 2023 - Springer
Abstract The Coronavirus disease 2019 (COVID-19) epidemic has triggered a huge impact
on healthcare, socioeconomics, and other aspects of the world over the past three years. An …

COVID-19 in thrombosis research: An editorial perspective

S Barco, SM Bates, HH Versteeg… - Thrombosis …, 2021 - thrombosisresearch.com
The coronavirus disease (COVID-19) pandemic has impacted every aspect of our lives.
Scientific research has not been spared. In the face of this global health emergency …